An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing
Open Access
- 10 June 2011
- journal article
- other
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 39 (4), 716-744
- https://doi.org/10.1177/0192623311406935
Abstract
Data collected from 182 marketed and nonmarketed pharmaceuticals demonstrate that there is little value gained in conducting a rat two-year carcinogenicity study for compounds that lack: (1) histopathologic risk factors for rat neoplasia in chronic toxicology studies, (2) evidence of hormonal perturbation, and (3) positive genetic toxicology results. Using a single positive result among these three criteria as a test for outcome in the two-year study, fifty-two of sixty-six rat tumorigens were correctly identified, yielding 79% test sensitivity. When all three criteria were negative, sixty-two of seventy-six pharmaceuticals (82%) were correctly predicted to be rat noncarcinogens. The fourteen rat false negatives had two-year study findings of questionable human relevance. Applying these criteria to eighty-six additional chemicals identified by the International Agency for Research on Cancer as likely human carcinogens and to drugs withdrawn from the market for carcinogenicity concerns confirmed their sensitivity for predicting rat carcinogenicity outcome. These analyses support a proposal to refine regulatory criteria for conducting a two-year rat study to be based on assessment of histopathologic findings from a rat six-month study, evidence of hormonal perturbation, genetic toxicology results, and the findings of a six-month transgenic mouse carcinogenicity study. This proposed decision paradigm has the potential to eliminate over 40% of rat two-year testing on new pharmaceuticals without compromise to patient safety.Keywords
This publication has 46 references indexed in Scilit:
- A Critical Review of the Effectiveness of Rodent Pharmaceutical Carcinogenesis Testing in Predicting for Human RiskVeterinary Pathology, 2011
- Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human NeoplasiaInternational Journal of Toxicology, 2010
- Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent AssaysToxicologic Pathology, 2010
- Alcohol and cancerThe Lancet Oncology, 2006
- Prediction of Rodent Carcinogenesis: An Evaluation of Prechronic Liver Lesions as Forecasters of Liver Tumors in NTP Carcinogenicity StudiesToxicologic Pathology, 2004
- Human Carcinogenic Risk Evaluation: An Alternative Approach to the Two-Year Rodent BioassayToxicological Sciences, 2004
- Mechanisms of Hormone-Mediated Carcinogenesis of the OvaryToxicologic Pathology, 2004
- Recommended Tissue List for Histopathologic Examination in Repeat-Dose Toxicity and Carcinogenicity Studies: A Proposal of the Society of Toxicologic Pathology (STP)Toxicologic Pathology, 2003
- Mechanistic Data and Risk Assessment of Selected Toxic End Points of the Thyroid GlandToxicologic Pathology, 1997
- Neoplastic Lesions of Questionable Significance to HumansToxicologic Pathology, 1994